Association between KOOS scores and OTC analgesic use in patients using knee-braces

DOCUMENT: SAR-2022-023-AD-v01

From: Felipe Figueiredo **To:** amandadavis139 (fiverr.com)

2022-05-03

TABLE OF CONTENTS

Association between KOOS scores and OTC analgesic use in patients using knee-braces

Document version

Version	Alterations
01	Initial version

1 ABBREVIATIONS

2 CONTEXT

2.1 Objectives

2.2 Data reception and cleaning

3 METHODS

3.1 Study parameters

3.1.1 Study design

3.1.2 Inclusion and exclusion criteria

3.1.3 Exposures

3.1.4 Outcomes

3.1.5 Covariates

3.2 Statistical analyses

This analysis was performed using statistical software R version 4.1.3.

4 RESULTS

4.1 Study population and follow up

Table 1 *caption*

Baseline characteristics	N = 10
Sex, n (%)	
F	7 (70%)
M	3 (30%)
Age (years), Mean (SD)	49 (12)
VAS score, Mean (SD)	7.70 (2.31)
KOOS score, Mean (SD)	0.48 (0.14)



Figure 1 *caption*

Table 2 caption

Characteristic	N = 10
Change in KOOS score, Mean (SD)	0.25 (0.14)
Change in VAS score, Mean (SD)	-6.10 (1.97)
Frequency of use (weekly), n (%)	
0	5 (50%)
1	5 (50%)

4.2 Inferential analysis

Table 3 caption

Characteristic	Beta	95% CI	p-value
Crude estimate	-0.08	-0.29 to 0.13	0.420
Controlled for VAS reduction	-0.10	-0.35 to 0.14	0.352
Controlled for sex and age	0.00	-0.22 to 0.22	0.990
Controlled for VAS reduction, sex and age	-0.05	-0.26 to 0.16	0.557

5 OBSERVATIONS AND LIMITATIONS

6 CONCLUSIONS

7 REFERENCES

- **SAP-2022-023-AD-v01** – Analytical Plan for Association between KOOS scores and OTC analgesic use in patients using knee-braces

8 APPENDIX

8.1 Exploratory data analysis



Figure A1 *Distribution of age in the study population.*



8.2 Modeling strategy

Table A1 *caption*

Characteristic	Beta	95% CI	p-value	Beta	95% CI	p-value	Beta	95% CI	p-value	Beta	95% CI	p-value
Frequency of use (weekly)												
0	—	—		—	—							
1	-0.08	-0.29 to 0.13	0.420	-0.10	-0.35 to 0.14	0.352	0.00	-0.22 to 0.22	0.990	-0.05	-0.26 to 0.16	0.557
Change in VAS score				0.02	-0.05 to 0.08	0.544				0.05	-0.02 to 0.13	0.138
Sex												
F												
M							-0.09	-0.32 to 0.13	0.345	-0.24	-0.52 to 0.05	0.091
Age (years)							-0.01	-0.02 to 0.00	0.098	-0.01	-0.02 to 0.00	0.113

8.3 Availability

All documents from this consultation were included in the consultant's Portfolio.

The portfolio is available at:

https://philsf-biostat.github.io/SAR-2022-023-AD/

8.4 Analytical dataset

Table A2 shows the structure of the analytical dataset.

Table A2 *Analytical dataset structure*

id	age	sex	pain_pre	koos_pre	outcome	pain_reduc	frequency
1							
2							
3							
…							
N							

Due to confidentiality the data-set used in this analysis cannot be shared online in the public version of this report.